Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism.

• Objective: Patients with hypopituitarism have adverse cardiovascular morbidity and reduced bone mineral density (BMD). The objective of this study was to analyze the effects of glucocorticoid (GC) replacement on cardiovascular risk factors and BMD in patients with hypopituitarism. Design, patients and methods: This was a cross-sectional study on 365 patients with hypopituitarism. Two-hundred and four patients (56%) were ACTH insufficient (ACTHins), receiving a mean ± SD hydrocortisone equivalent (HCeq) dose of 20.5 ± 5.8 mg/day. The difference in BMD and cardiovascular risk profile between ACTH sufficient (ACTHsuff) and ACTHins patients, before commencement of GH replacement, was analyzed by multiple linear and logistic regression. Results: ACTHins was independently associated with lower fasting glucose but not other cardiovascular risk factors. The mean HCeq dose per kg body weight was 15% higher in ACTHins women than in ACTHins men (P = 0.009). In women, ACTHins was independently associated with decreased BMD at the lumbar spine (P = 0.002) and femoral neck (P = 0.006) and the presence of osteopenia (P = 0.004). BMD was not different between ACTHins and ACTHsuff men. Conclusion: The current average HCeq dose of approximately 20 mg per day is not associated with an adverse metabolic profile, as compared with ACTHsuff hypopituitary patients. GC replacement in ACTHins women is independently associated with reduced BMD and higher prevalence of osteopenia.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Dermatologi och venereologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Dermatology and Venereal Diseases (hsv//eng)

Publication and Content Type

ref (subject category)

art (subject category)